Abstracts tagged "interleukins (IL) and takayasu arteritis"

Abstract Number: 864 • 2016 ACR/ARHP Annual Meeting
Takayasu Arteritis Developed over the Age of 40 Has Lower Levels of Interferon Gamma and Interleukin 17 at Disease Onset and Fewer Subsequent Relapses
Shoichi Fukui¹, Naoki Iwamoto², Toshimasa Shimizu², Masataka Umeda², Ayako Nishino³, Yoshiro Horai², Tomohiro Koga⁴, Shin-ya Kawashiri⁵, Kunihiro Ichinose¹, Yasuko Hirai², Mami Tamai¹, Hideki Nakamura⁵, Tomoki Origuchi⁶, Kiyoshi Migita⁷, Yukitaka Ueki⁸ and Atsushi Kawakami⁹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki Universit, Nagasaki, Japan, ⁴Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁷Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ⁸Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, ⁹Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis (TAK) include age at disease onset ≤ 40 years. We aimed…
Abstract Number: 3043 • 2015 ACR/ARHP Annual Meeting
IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis
Ali Ugur Unal¹, Rabia Deniz², Aysin Tulunay Virlan³, Filiz Ture Ozdemir³, Imren Aydin Tatli³, Gulsen Ozen¹, Fatma Alibaz-Oner⁴, Gonca Mumcu⁵, Tulin Ergun⁶ and Haner Direskeneli¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁶Dermatology, Marmara University Faculty of Medicine, Dermatology, Istanbul, Turkey
Background/Purpose: Interleukin-17 (IL-17) has been associated with the pathogenesis of various inflammatory diseases. The aim of our study was to investigate the expression of Th17-related…
Abstract Number: 3056 • 2015 ACR/ARHP Annual Meeting
Increased Circulating Th17 Cells, Serum IL-17 and Serum IL-23 in Takayasu’s Arteritis
Ramnath Misra, Durga Prasanna Misra and Smriti Chaurasia, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: The immune mechanisms underlying Takayasu’s arteritis (TA) are not clear. Expanded Th17 T cell subset has been demonstrated in Giant Cell Arteritis. Gamma delta…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].